Published in J Control Release on June 27, 2015
Combination therapy of stem cell derived neural progenitors and drug delivery of anti-inhibitory molecules for spinal cord injury. Acta Biomater (2015) 0.79
Stem cells for spinal cord injury: Strategies to inform differentiation and transplantation. Biotechnol Bioeng (2016) 0.77
Drug-nanoencapsulated PLGA microspheres prepared by emulsion electrospray with controlled release behavior. Regen Biomater (2016) 0.75
Local Release of Paclitaxel from Aligned, Electrospun Microfibers Promotes Axonal Extension. Adv Healthc Mater (2016) 0.75
Tissue Engineering Approaches to Modulate the Inflammatory Milieu following Spinal Cord Injury. Cells Tissues Organs (2016) 0.75
Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord. Front Pharmacol (2017) 0.75
Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature (2002) 8.22
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials (2000) 4.42
Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature (2000) 4.30
Myelination in rat brain: method of myelin isolation. J Neurochem (1973) 4.01
Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature (2002) 3.81
Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science (2002) 3.50
Restoring voluntary control of locomotion after paralyzing spinal cord injury. Science (2012) 3.40
Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature (2002) 3.33
Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev (1996) 2.98
Rho signaling pathway targeted to promote spinal cord repair. J Neurosci (2002) 2.90
PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science (2009) 2.84
Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci (2003) 2.76
Interactions of sugars with membranes. Biochim Biophys Acta (1988) 2.64
Nerve regeneration restores supraspinal control of bladder function after complete spinal cord injury. J Neurosci (2013) 2.43
The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. Exp Neurol (2003) 2.28
Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci (2003) 2.23
Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol (2005) 2.22
The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials (2004) 2.12
The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci (2003) 2.11
Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci (2010) 2.08
A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma (2010) 1.95
NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat Neurosci (2012) 1.94
Combined intrinsic and extrinsic neuronal mechanisms facilitate bridging axonal regeneration one year after spinal cord injury. Neuron (2009) 1.76
Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst (1995) 1.73
Leukocyte common antigen-related phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. J Neurosci (2011) 1.52
Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded guidance channels after spinal cord injury. FASEB J (2003) 1.49
Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci U S A (2009) 1.48
Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. J Neurosci (2001) 1.46
Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cord. J Neurotrauma (2005) 1.43
Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. J Neurosci (2007) 1.38
Stem cell therapies for spinal cord injury. Nat Rev Neurol (2010) 1.35
Neurotrophins support regenerative axon assembly over CSPGs by an ECM-integrin-independent mechanism. J Cell Sci (2006) 1.35
Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS One (2012) 1.30
Differential effects of anti-Nogo-A antibody treatment and treadmill training in rats with incomplete spinal cord injury. Brain (2009) 1.25
Advances in stem cell therapy for spinal cord injury. J Clin Invest (2012) 1.24
Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat. Neurorehabil Neural Repair (2007) 1.23
Scar-mediated inhibition and CSPG receptors in the CNS. Exp Neurol (2012) 1.14
Combination treatment with anti-Nogo-A and chondroitinase ABC is more effective than single treatments at enhancing functional recovery after spinal cord injury. Eur J Neurosci (2013) 1.12
An in vivo study of the host tissue response to subcutaneous implantation of PLGA- and/or porcine small intestinal submucosa-based scaffolds. Biomaterials (2007) 1.11
Effect of preparation temperature on the characteristics and release profiles of PLGA microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. J Control Release (2000) 1.11
Tissue-engineered fibrin scaffolds containing neural progenitors enhance functional recovery in a subacute model of SCI. Soft Matter (2010) 1.09
Combination of engineered Schwann cell grafts to secrete neurotrophin and chondroitinase promotes axonal regeneration and locomotion after spinal cord injury. J Neurosci (2014) 1.08
Transplants of fibroblasts expressing BDNF and NT-3 promote recovery of bladder and hindlimb function following spinal contusion injury in rats. Exp Neurol (2005) 1.06
Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury. J Neurosci (2014) 1.05
Conditioning lesions before or after spinal cord injury recruit broad genetic mechanisms that sustain axonal regeneration: superiority to camp-mediated effects. Exp Neurol (2011) 1.04
Chronic intrathecal infusions after spinal cord injury cause scarring and compression. Microsc Res Tech (2001) 1.04
Combinatorial strategies with Schwann cell transplantation to improve repair of the injured spinal cord. Neurosci Lett (2009) 1.03
Sustained release of neurotrophin-3 and chondroitinase ABC from electrospun collagen nanofiber scaffold for spinal cord injury repair. J Biomed Mater Res A (2011) 0.99
Adult stem cell transplants for spinal cord injury repair: current state in preclinical research. Curr Stem Cell Res Ther (2011) 0.97
A multi-domain fragment of Nogo-A protein is a potent inhibitor of cortical axon regeneration via Nogo receptor 1. J Biol Chem (2011) 0.97
Role of Rho kinase pathway in chondroitin sulfate proteoglycan-mediated inhibition of neurite outgrowth in PC12 cells. J Neurosci Res (2008) 0.96
Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release (2000) 0.96
NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J Control Release (1998) 0.95
Lipid-based microtubular drug delivery vehicles. J Control Release (2001) 0.95
Sustained release of BMP-2 in a lipid-based microtube vehicle. Acta Biomater (2008) 0.94
Structure of polymerizable lipid bilayers. I--1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine, a tubule-forming phosphatidylcholine. Chem Phys Lipids (1988) 0.92
Rho-ROCK inhibition in the treatment of spinal cord injury. World Neurosurg (2013) 0.90
Controlled release of chondroitinase ABC from fibrin gel reduces the level of inhibitory glycosaminoglycan chains in lesioned spinal cord. J Control Release (2010) 0.89
cAMP-responsive element-binding protein (CREB) and cAMP co-regulate activator protein 1 (AP1)-dependent regeneration-associated gene expression and neurite growth. J Biol Chem (2014) 0.88
Effect of additives on the release of a model protein from PLGA microspheres. AAPS PharmSciTech (2001) 0.88
Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury. Biomaterials (2010) 0.88
Chondroitin sulfate proteoglycans in spinal cord contusion injury and the effects of chondroitinase treatment. J Neurotrauma (2007) 0.88
Spinal cord injury facts and figures at a glance. J Spinal Cord Med (2012) 0.85
Controlled release of transforming growth factor-beta from lipid-based microcylinders. J Microencapsul (1995) 0.82
Design of protein-releasing chitosan channels. Biotechnol Prog (2009) 0.81
Acidic pH rapidly increases immunoreactivity of glial fibrillary acidic protein in cultured astrocytes. Glia (1995) 0.80
Survival, Differentiation, and Migration of High-Purity Mouse Embryonic Stem Cell-derived Progenitor Motor Neurons in Fibrin Scaffolds after Sub-Acute Spinal Cord Injury. Biomater Sci (2014) 0.80
The effects of combining chondroitinase ABC and NEP1-40 on the corticospinal axon growth in organotypic co-cultures. Neurosci Lett (2010) 0.79
Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres. Vaccine (2002) 0.78
Affinity-based release of chondroitinase ABC from a modified methylcellulose hydrogel. J Control Release (2013) 0.77
New method for analysis of biodegradable polyesters by high-performance liquid chromatography after alkali hydrolysis. Biomaterials (1992) 0.77
Impact of treatment duration and lesion size on effectiveness of chondroitinase treatment post-SCI. Exp Neurol (2015) 0.76
Sustained Delivery of Chondroitinase ABC from Hydrogel System. J Funct Biomater (2012) 0.75